Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab for Persistent Redness and Flushing in Rosacea
NCT04419259Phase 2Unknown
- Start
- Jun 2020
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erenumab in rosacea. Status: unknown.
02
Drugs
erenumab
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT04419259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04419259.